Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Xianxiu Ji"'
Publikováno v:
Cancer Cell International, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Background m6A modification has close connection with the occurrence, development, and prognosis of tumors. This study aimed to explore the roles of m6A modification and its related mechanisms in non-small cell lung cancer (NSCLC). Methods N
Externí odkaz:
https://doaj.org/article/032f5b0c05514282bba0284cc8a99378
Autor:
Juan Zhou, Minwei Bao, Guanghui Gao, Yiran Cai, Lihong Wu, Lei Lei, Jing Zhao, Xianxiu Ji, Ying Huang, Chunxia Su
Publikováno v:
BMC Medicine, Vol 20, Iss 1, Pp 1-14 (2022)
Abstract Background The combination of immune checkpoint inhibitors (ICIs) and chemotherapy has been the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with driver-gene negative. However, efficacy biomarkers fo
Externí odkaz:
https://doaj.org/article/79013bb61c8b4eb9a2592324c731442f
HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Multiple oncogenic molecular alterations have been discovered that serve as potential drug targets in non-small cell lung cancer (NSCLC). While the pathogenic and pharmacological features of common targets in NSCLC have been widely investigated, thos
Externí odkaz:
https://doaj.org/article/2c173d1ea30b4c76ae7a263ee2d86cd8
Publikováno v:
Journal of International Medical Research, Vol 49 (2021)
Objective To compare the baseline clinical characteristics between patients with ROS1 -positive and ALK -positive advanced non-small cell lung cancer (NSCLC), and the correlations of these subtypes with the distribution of metastases. Methods We comp
Externí odkaz:
https://doaj.org/article/96cd78b31e234bcd8443401914fc4ce5
Autor:
Qinfang Deng, Boxiong Xie, Leilei Wu, Xianxiu Ji, Chao Li, Li Feng, Qiyu Fang, Yuchen Bao, Jialu Li, Shengnan Jin, Chunming Ding, Yixue Li, Songwen Zhou
Publikováno v:
Heliyon, Vol 4, Iss 12, Pp e01031- (2018)
Purpose: Although many studies have reported on the resistance mechanism of first-generation EGFR TKIs (1st EGFR TKIs) treatment, large-scale dynamic ctDNA mutation analysis based on liquid biopsy for non-small cell lung cancer (NSCLC) in the Chinese
Externí odkaz:
https://doaj.org/article/8bd9179608044c05a0b014eb374240cc
Publikováno v:
BioMed Research International. 2022:1-15
Heparan sulfate proteoglycan is a key component of cell microenvironment and plays an important role in cell-cell interaction, adhesion, migration, and signal transduction. Heparan sulfate 3-O-sulfotransferase 1 (HS3ST1) is a metabolic-related gene o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38c47bd60ae9938cd94e18e001794551
https://doi.org/10.1155/2022/5509346
https://doi.org/10.1155/2022/5509346
Autor:
Chunxia Su, Juan Zhou, Huiping Qiang, Jing Zhao, Qing Chang, Xianxiu Ji, Jiaqi Li, Mengqing Xie, Tianqing Chu
Publikováno v:
International journal of cancerREFERENCES. 152(1)
Global phase 3 trials have demonstrated the priority of several next-generation anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs). However, clinical studies are conducted with specific populations that differ from the real world. The s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef47f0428c7949bfba1dbaddd34be8f7
https://pubmed.ncbi.nlm.nih.gov/35579989
https://pubmed.ncbi.nlm.nih.gov/35579989
Publikováno v:
The Journal of International Medical Research
Objective To compare the baseline clinical characteristics between patients with ROS1-positive and ALK-positive advanced non-small cell lung cancer (NSCLC), and the correlations of these subtypes with the distribution of metastases. Methods We compar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0a3e99681823f41d183e7bd68ccec04
http://europepmc.org/articles/PMC7890737
http://europepmc.org/articles/PMC7890737
Publikováno v:
Cancer biomarkers : section A of Disease markers. 27(3)
BACKGROUND AND OBJECTIVE Chemotherapy remains the basis of the treatment of lung cancer, and screening biomarkers with predictive value for chemotherapy is of great interest. The present study focused on status of genes methylation in NSCLC patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a03788914f3048e52b8f4b99eebc7654
https://pubmed.ncbi.nlm.nih.gov/31839603
https://pubmed.ncbi.nlm.nih.gov/31839603
Publikováno v:
Journal of Cancer
Gefitinib is a potent inhibitor of EGFR and represents the front-line treatment for non-small cell lung cancer (NSCLC) therapeutics. However, NSCLC patients are prone to develop acquired resistance through as yet, undefined mechanisms of resistance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b468edb5b7f45a5ac68aadfde5658b5
https://pubmed.ncbi.nlm.nih.gov/32284763
https://pubmed.ncbi.nlm.nih.gov/32284763